Basket Updated
0
Items added
Watch this webinar to learn how the new CAR linker antibodies can interrogate the expression of an entire panel of CARs.
Anti-CAR linker antibodies confirm CAR surface expression for CAR-T therapy, regardless of antigen specificity; 2023 winner of the CiteAb Innovation Award.
To enable surface characterization of chimeric antigen receptors (CARs), scientists at CST developed versatile and specific antibodies that detect the linker sequence of scFv domains. Watch the poster presentation from AACR.
Innovative anti-linker monoclonal antibodies from CST eliminate the need to develop unique detection reagents for every new chimeric antigen receptor (CAR) molecule developed, speeding detection in flow cytometry panels.
Learn about the antibodies, custom reagents, and ready-to-use cell assay kits to support your CAR-T therapy development.
Checkpoint inhibitors, targeted antibodies, adoptive cell therapy, and cancer vaccines are promising immunotherapies with recent therapeutic developments.
At AACR 2023, many presentations focused on topics including cancer immunology, CAR-T therapy, spatial biology, mRNA vaccines, and KRAS.
CST Media Room
Interact with this CAR-T signaling pathway to learn how the combination of extracellular and intracellular domains, including CD8, CD28, 4-1BB, OX40, or CD27, exert antitumor effects.
Harnessing the power of the immune system's T cells to attack and treat cancer is a promising research area that may lead to highly effective therapies.
GPNMB is an attractive therapeutic target for antibody-based therapeutics, and is currently being evaluated for its potential in treating triple-negative breast cancer and other metastatic cancers. Let's explore the strategy behind one type of immunotherapeutics, antibody-drug conjugates (ADCs).
Quit living in the past! The future of cars is electric.
Lymphoma is a cancer of the lymphatic system, a key part of the body’s immune system. Treatment options & patient prognoses differ based on lymphoma type.
Recent advancements including next-generation proteasome inhibitors, monoclonal bispecific antibodies, antibody-drug conjugates, and CAR-T therapies that have changed the therapeutic landscape for multiple myeloma.
World Cancer Day raises awareness for cancer prevention, detection, and treatment. Learn about the scientific breakthroughs that are closing the care gap.
Targeting B-Cell Maturation Antigen Holds Promise for Multiple Myeloma Cure. B Cells, TNFR, CAR-T, hematopoietic, bone marrow, BCMA, ADCs, Multiple myeloma
Explore the complex inflammation signaling pathways. Click here to learn more and understand the molecular basis of inflammation.
In an effort to curb carbon emissions, highway congestion and promote employee wellbeing, CST drafted an Alternative Transportation Plan (ATP).
A scientific resource for the BIR protein domain containing information on structure, function, and domain binding in apoptosis.
Our immune system has the ability to detect and fight infectious pathogens. But over time, cancers can evolve and evade the immune response.
Cell Signaling Technology pathways by research area
Diverse selection of antibodies to generate critical information for the development of novel immunotherapies and insights into the role of immune cells and inflammation in disease.
A scientific resource for the SWIRM protein domain containing information on structure, function, and binding to either DNA or acetylated lysine residues during chromatin remodeling.
Advancements in immunotherapeutics against cancer include receptor agonists, adoptive cell transfer, anti-cancer vaccines, and combination therapies.
Immunotherapy harnesses the power of the immune system to fight immunodeficiences, autoimmune diseases, and cancer. Manipulating the immune system to attack harmful cells is an area of intense research.
Expert-reviewed diagram providing a current overview of the m6A RNA pathway with references to its role in tumor development
